1. Scrip
  2. >>Business

Ovarian Cancer Market Snapshot: AstraZeneca's Lynparza Poised To Lead In Niche Space

 
• By Emily Hayes

AstraZeneca's Lynparza, Tesaro's Zejula and Clovis' Rubraca have brought much needed advances to patients with ovarian cancer, but the market is relatively small and the competition intense, while unmet need remains high.

Business man showing pie chart in color background

Long in need of therapeutic advances beyond chemotherapy, the ovarian cancer market is flush with new treatment options, including three poly-ADP ribose polymerase (PARP) inhibitors in the maintenance treatment arsenal and a new approval for Roche's Avastin in the front-line setting. But it's still unclear how much room there is for commercial success.

So far, the first-to-market PARP inhibitor – AstraZeneca PLC's Lynparza (olaparib), partnered with Merck & Co. Inc. since mid-2017 – has a big edge (see chart) over its rivals: Clovis Oncology Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.